ILP-2 Peptide

Details for Product No. ABIN500019
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Protein Name
Origin
Human
(2)
Source
Synthetic
Application
Control Peptide (CP)
Pubmed 4 references available
Quantity 50 μg
Shipping to United States (Change)
Availability Discontinued
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Catalog No. ABIN500019
170.50 $
Plus shipping costs $45.00
Add to Basket

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Specificity 12 amino amino terminus of human ILP-2.
Purification purified
Alternative Name BIRC8 / ILP2
Background Synonyms: Baculoviral IAP repeat-containing protein 8, IAP-like protein 2, ILP-2, Inhibitor of apoptosis-like protein 2, Testis-specific inhibitor of apoptosis
Gene ID 112401
NCBI Accession NP_203127
UniProt Q96P09
Research Area Apoptosis/Necrosis
Application Notes ILP-2 peptide is used for blocking the antibody activity of ILP-2. It usually blocks theantibody activity completely in Western blot by incubating the peptide with equal volumeof antibody for 30 min at 37 °C.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Concentration 0.2 mg/mL
Buffer PBS containing 0.02 % sodium azide
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Avoid repeated freezing and thawing.
Storage -20 °C
Storage Comment Store at -20 °C.
Background publications Inohara, Koseki, del Peso et al.: "Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB." in: The Journal of biological chemistry, Vol. 274, Issue 21, pp. 14560-7, 1999 (PubMed).

Ogura, Inohara, Benito et al.: "Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB." in: The Journal of biological chemistry, Vol. 276, Issue 7, pp. 4812-8, 2001 (PubMed).

Hugot, Chamaillard, Zouali et al.: "Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease." in: Nature, Vol. 411, Issue 6837, pp. 599-603, 2001 (PubMed).

Ogura, Bonen, Inohara et al.: "A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease." in: Nature, Vol. 411, Issue 6837, pp. 603-6, 2001 (PubMed).

Validation Images
back to top